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Abstract 
Background: The incidence of postoperative nausea and vomiting (PONV) remains high. The 
effects of sufentanil for PONV is not firmly confirmed. The aim of this study was to compare the 
effect of sufentanil- and fentanyl-based intravenous patient-controlled analgesia (IV-PCA) on the 
incidence of PONV after laparoscopic nephrectomy.  
Methods: Eighty-six patients were randomly allocated to receive either the sufentanil (n =43) or 
fentanyl (n =43). IV-PCA was prepared using either sufentanil 3 µg/kg or fentanyl 20 µg/kg, 
ramosetron 0.3 mg, and ketorolac 120 mg. The primary outcome of was the incidence of PONV 
during 24 h after post anesthesia care unit (PACU) discharge. The secondary outcomes were the 
modified Rhodes index and patient satisfaction scores at 24 h after PACU discharge, need for rescue 
antiemetics, pain score, need for additional analgesics, and cumulative consumption of IV-PCA 
Results: The incidence of PONV was comparable between the sufentanil and fentanyl groups 
(64.3% vs. 65%, p = 0.946; respectively). The number of patients who required antiemetics (p = 
0.946) and the modified Rhodes index at 24 h after post-anesthesia care unit discharge (p = 0.668) 
were also comparable in both groups. No significant differences were found in the secondary 
outcomes, including the analgesic profiles and adverse events between the groups.  
Conclusions: In conclusion, sufentanil- and fentanyl-based IV-PCA showed similar incidence of 
PONV with comparable analgesic effects after laparoscopic nephrectomy. Based on these results, 
we suggest that sufentanil and fentanyl may provide comparable effects for IV-PCA after 
laparoscopic nephrectomy. 
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Introduction 
Intravenous patient-controlled analgesia 
(IV-PCA), which is based on strong opioids, is widely 
used for postoperative pain relief. Among these 
opioids, the three synthetic ones, alfentanil, fentanyl 
and sufentanil are the most common in anesthetic 
practice. Opioids act mainly on mu-receptors and 
exhibit powerful analgesic effects; however, inevitable 








vomiting (PONV) are frequently encountered. 
Opioids are indeed a double-edged sword for PONV, 
because insufficient pain control after surgery itself is 
a risk factor for PONV while the incidence of PONV is 
dose-dependent with opioids.[1,2]  
PONV decreases patient satisfaction, and may 
adversely affect prognosis by increasing wound 
dehiscence and dehydration, which may result in 
aspiration pneumonia and delayed recovery.[3,4] The 
pathogenesis of PONV involves multiple pathways, 
including pain, anxiety, surgery-related factors and 
stimulation of the chemoreceptor trigger zone (CTZ) 
by anesthetics or opioids via neurotransmitters (e.g., 
dopamine, acetylcholine, histamine and serotonin). 
These factors often influence and/or overlap with 
each other, leading to PONV.[1,5] To date, no single 
strategy has conclusively demonstrated an ability to 
prevent PONV.  
 Although laparoscopic surgery is considered 
advantageous due to the lower risk of postoperative 
pain and bleeding than open surgery, but it is 
classified as high-risk surgery for PONV due to the 
use of carbon dioxide (CO2) for 
pneumoperitoneum.[1,6] In this subset of patients, the 
incidence of PONV has been reported to be as high as 
50-75%.[1,6] Thus, these high-risk patients might be 
targeted for PONV prevention by eliminating 
correctable risk factors, such as opioid dose reduction 
or proper pain management.[1,4] 
 Fentanyl is often used to control postoperative 
pain because of its relatively fast effect and short 
duration, whereas its incidence of PONV is relatively 
high.[7,8] Sufentanil has a faster onset of action due to 
its higher affinity for mu-opioid receptors, lipophilic 
properties, and easier passage through the 
blood-brain barrier; therefore, it exhibits the most 
potent analgesic effect among clinically applied 
opioids.[9-12] Additionally, although previous 
studies have yielded conflicting results, it is known 
that sufentanil is associated with a lower incidence of 
PONV than fentanyl due to its structural 
properties.[13,14] However, limited data are available 
comparing these two drugs on the incidence and 
severity of PONV in patients undergoing laparoscopic 
nephrectomy who are at high risk for PONV. 
Therefore, we designed this double-blind randomized 
controlled study to compare the fentanyl and 
sufentanil-based IV-PCA on the incidence and 
severity of PONV in patients undergoing laparoscopic 
nephrectomy.  
Methods 
This study was conducted at Severance Hospital, 
Yonsei University Health System, Seoul, Korea, 
approved by our institutional review board (IRB 
number, 4-2017-0201), and registered at 
http://www.ClinicalTrials.gov (NCT03171610). 
Written informed consent was obtained from each 
patient before study enrollment.  
Patients 
Eighty-six patients, aged 20 to 70 years, with an 
American Society of Anesthesiologists (ASA) physical 
status I–III scheduled for elective laparoscopic or 
robot-assisted laparoscopic nephrectomy, and who 
required IV-PCA for postoperative pain control were 
enrolled. Patients were excluded if they met at least 
one of the following criteria: (1) long-term use of 
opioids, pain killers or tranquilizers; (2) a history of 
diabetic neuropathy; (3) a prolonged prothrombin 
time or an activated partial thromboplastin time; (4) 
cognitive function impairment; (5) obesity (body mass 
index ≥ 30 kg/m2); (6) conversion from a laparoscopic 
to open surgery; or (7) reoperation within 24 h. 
Patients were randomly assigned to either 
sufentanil (n = 43) or fentanyl group (n = 43). 
Randomization was performed by 
computer-generated randomized numbers. For each 
patient, group assignments were kept in a 
sequentially numbered sealed, opaque envelope. An 
investigator who was not involved with outcome 
measurement and patient care opened the envelope 
on the day of surgery and prepared the IV-PCA 
according to the group assignment. 
Anesthetic management and Intervention 
Premedication was not administered. After 
applying standard monitoring devices, general 
anesthesia was induced with propofol 2 mg/kg, 
remifentanil 1µg/kg, and rocuronium 0.8 mg/kg. 
Anesthesia was maintained with sevoflurane or 
desflurane, with 50 % oxygen in air, and remifentanil 
0.1 to 0.2 µg/kg/min. The depth of anesthesia was 
controlled using a bispectral index (BIS) between 45 
and 50. Propacetamol 15 mg/kg in total of 100 ml of 
0.9 % normal saline was administered 20 min before 
the end of surgery, and fentanyl 1 µg/kg was injected 
10 min before the end of surgery for postoperative 
pain prophylaxis. Ramosetron 0.3 mg was 
administered at the end of surgery for nausea 
prophylaxis, followed by continuous infusion of 
IV-PCA. 
IV-PCA was prepared using either sufentanil 3 
µg/kg or fentanyl 20 µg/kg, ramosetron 0.3 mg, and 
ketorolac 120 mg in 0.9% normal saline with a total 
volume of 100 ml according to the group assignment. 
We administered fentanyl and sufentanil with a 
potency ratio of 1:7, based on results from a previous 
study.[14] The PCA device (Ambix anapa, Ewha 
Fresenius Kabi Inc., Gyeonggi-do, Korea) was 




programmed to deliver 2 mL/h as the background 
infusion with a 0.5 ml bolus at a 15-min lockout 
period.  
Assessments 
After surgery, patients were asked to report their 
nausea and vomiting upon arrival at the 
post-anesthesia care unit (PACU); 30 min after arrival 
at PACU; 1, 6, and 24 h after discharge from the 
PACU on a binary scale (yes or no). The severity of 
pain at rest and coughing was also assessed at the 
same interval using a verbal numerical rating scale 
(VNRS), where 0 means no pain and 10 is the worst 
imaginable. Intravenous metoclopramide 10 mg was 
given as a rescue antiemetic at the patients’ request. If 
severe nausea persisted after two consecutive rescue 
antiemetics, PCA was stopped for 2 h and restarted 
later when the symptoms subsided. Patients were 
allowed to receive intravenous pethidine 25 mg when 
they complained of pain >4 on VNRS. The Ramsay 
sedation score and cumulative consumption of 
IV-PCA were recorded at the same interval to 
evaluate postoperative sedation due to opioid use. 
The modified Rhodes index score [15] was assessed to 
evaluate the severity of PONV at 24 h after PACU 
discharge. Patients were asked about their satisfaction 
with IV-PCA for the previous 24 hours, using a scale 
with 0 meaning not satisfied to 10 meaning to very 
satisfied. Any adverse events, such as pruritis and 
dizziness, were evaluated. Patients were assessed by a 
trained nurse who was blinded to the group 
assignment. 
The primary outcome of this study was the 
incidence of PONV 24 h after PACU discharge. The 
secondary outcomes were the modified Rhodes index 
and patient satisfaction scores at 24 h after PACU 
discharge, pain score, the need for rescue antiemetics 
or additional analgesics, and cumulative consumption 
of IV-PCA. The time to first flatus was also assessed. 
Statistical analysis 
Sample size was calculated based on the 
previous studies that addressed the incidence of 
PONV in patients using fentanyl- or sufentanil-based 
IV-PCA for postoperative pain relief after various 
laparoscopic surgeries.[16-23] The average incidence 
of PONV during 24 h were 39% and 17% during in the 
fentanyl and sufentanil groups, respectively. Based on 
these findings, we assumed a 20% difference in the 
incidence of PONV between the two groups. 
Therefore, 39 patients were required in each group to 
obtain a power of 80% with an alpha of 0.05. 
Considering a 10 % dropout rate, we decided to enroll 
43 patients in each group.  
Statistical analysis was performed using SPSS 25 
(SPSSFW, SPSS, IBM, Armonk, NY, USA). Continuous 
variables were expressed as mean ± standard 
deviation (SD) or median [interquartile range] and 
were compared using Student’s t test or the 
Mann-Whitney U test, as appropriate. Dichotomous 
variables were expressed as the number of patients 
(percentage) and were compared using Chi-square 
and or Fisher’s exact test, as appropriate. For 
secondary analysis, Bonferroni correction was 
performed to compare inter-group differences of five 
time-points. P values of <0.05 were considered 
statistically significant. 
Results 
Between June 2017 and January 2018, a total of 86 
patients were enrolled. One patient in the sufentanil 
group and two patients in the fentanyl group were 
excluded because surgery was converted to open 
surgery. One patient in the fentanyl group was 
excluded after the reoperation within 24 h due to 
postoperative bleeding (Figure 1). 
Patients’ demographic data were similar 
between the groups (Table 1). PONV occurred in 27 
(64.3%) and 26 (65%) patients in the sufentanil and the 
fentanyl groups, respectively (p = 0.946) (Table 2). The 
number of patients who required antiemetics and the 
modified Rhodes index at 24 h after PACU discharge 
were comparable between the groups (Table 2). 
 
Table 1. Demographic data 
 sufentanil group (n = 
42) 
fentanyl group (n = 
40) 
P value 
Age (yr) 52 ± 9 49 ± 12 0.291 
Height (cm)  168 ± 8 165 ± 10 0.412 
Weight (kg) 67 ± 11 68 ± 11 0.812 
Female  15 (35.7%) 17 (42.5%) 0.651 
Apfel score 2.5 [2-3] 2.5 [2-3] 0.959 
Laparoscopic/Robotic 
surgery  
12/30 12/28 >0.999 
ASA I/II/III  21/19/2 23/15/2 0.809 
Hypertension 12 (28.6%) 11 (27.5%) >0.999 
Diabetes 3 (7.1%) 4 (10%) 0.709 
Anesthesia time (min) 213 [189 – 241] 195 [164 – 224] 0.168 
Data are presented as mean ± standard deviation or median (interquartile range) 
and numbers (%). 
ASA, American Society of Anesthesiologists. 
 
No differences were observed in the 
postoperative analgesic profiles, including pain scores 
at rest and during coughing, the number of patients 
who required analgesics, cumulative consumed 
volume of IV-PCA, the number of patients who 
clamped the IV-PCA, and the patient satisfaction 
score between the groups (Table 3). There were no 
significant differences in postoperative adverse events 
and Ramsay sedation score (Table 4). 
The number of patients who required 
antiemetics (26 vs. 3, p=0.001), stopped IV-PCA (36 vs. 




7, p <0.001) and reported dizziness (37 vs. 10, p=0.003) 
were higher in patients with PONV than in those 
without PONV, respectively. Postoperative analgesic 
profiles, time to flatus, and patient satisfaction score 
were not significantly different between patients with 
PONV and without PONV (data not shown). 
 
Table 2. The incidence of postoperative nausea and vomiting, 
modified Rhodes index, and use of rescue antiemetics. 
 sufentanil group (n 
= 42) 





   
 Overall  27 (64.3%)/ 4(9.5%) 26 (65%) / 4(10%) 0.946/ 
>0.999 
 PACU arrival 5 (11.9%)/0 (0%) 4 (10%)/0 (0%) >0.999/- 
 30 min at PACU  2 (4.8%)/0 (0%) 4 (7.5%)/0 (0%) 0.672/- 
 1 h after PACU discharge  9 (21.4%)/0 (0%) 11 (27.5%)/0 (0%) 0.522/- 
 6 h after PACU discharge 11 (26.2%)/3 (7.1%) 12 (30.0%)/ 2 (5%) 0.701/ 
>0.999 
 24 h after PACU 
discharge 
23 (54.8%)/ 4 (9.5%) 17 (42.5%)/ 4 (10%) 0.267/ 
>0.999 
Number of patients who required antiemetics 
 Overall  15 (35.7%) 14 (35%) 0.946 
 PACU arrival 4 (9.5%) 3 (7.5%) >0.999 
 30 min at PACU  2 (4.8%) 0 (0%) 0.494 
 1 h after PACU discharge  5 (11.9%) 4 (10%) >0.999 
 6 h after PACU discharge 6 (14.3%) 7 (17.5%) 0.690 
 24 h after PACU 
discharge 
7 (16.7%) 6 (15%) 0.836 
Modified Rhodes index 4 [0-9] 3 [0-8] 0.668 
Data are presented as numbers (%). 
PACU, postoperative anesthesia care unit. 
 
Table 3. Postoperative analgesic profiles 
 sufentanil group 
(n = 42) 
fentanyl group 
(n = 40) 
P value 
VNRS of pain (at rest/ during 
coughing) 
   
 PACU arrival 6 [3-7]/ 7 [5-8] 5 [4-7]/ 6 [5-8] 0.428/0.594 
 30 min at PACU  5 [3-5]/ 6 [4-7] 4 [4-5]/ 5 [4-6] 0.569/0.507 
 1 h after PACU discharge  5 [4-7]/ 7 [5-8] 5 [2-6]/6 [5-8] 0.428/0.403 
 6 h after PACU discharge 2 [0-4]/ 4 [2-6] 3 [1-4]/ 4 [3-8] 0.475/0.858 
 24 h after PACU discharge 1 [0-2]/ 4 [2-4] 1 [0-3]/ 4 [2-5] 0.614/0.839 
Number of patients who required analgesics 
 Overall  30 (71.4%) 28 (70%) >0.999 
 PACU arrival 24 (57.1%) 17 (42.5%) 0.269 
 30 min at PACU  6 (14.3%) 5 (12.5%) >0.999 
 1 h after PACU discharge  13 (31%) 10 (25%) 0.627 
 6 h after PACU discharge 5 (11.9%) 7 (17.5%) 0.543 
 24 h after PACU discharge 5 (11.9%) 7 (17.5%) 0.543 
Cumulative volume of IV-PCA consumed (mL) 
 PACU arrival 4 [2-5] 5 [3-6] 0.891 
 30 min at PACU  5 [4-8] 6 [4-8] 0.799 
 1 h after PACU discharge  10 [6-15] 9 [7-12] 0.962 
 6 h after PACU discharge 32 [21-42] 35 [20-40] 0.919 
 24 h after PACU discharge 56 [38-65] 50 [40-60] 0.688 
Number of patients who 
clamped the IV-PCA 
22 (52.4%) 21 (52.5%) >0.999 
Patient satisfaction score 4 [3-4] 4 [3-5] 0.394 
Data are presented as median (interquartile range) and numbers (%). 
IV-PCA, intravenous patient-controlled analgesia; PACU, post-anesthesia care unit; 





Figure 1. Consort flow diagram. 





Table 4. Postoperative adverse events and Ramsay sedation 
score 
 sufentanil group (n = 
42) 
fentanyl group (n = 
40) 
P value 
Time to flatus (h) 18 [12-27] 19 [14 - 23] 0.950 
Dizziness 25 (59.5%) 22 (55%) 0.824 
Pruritis 0 (0%) 1 (2.5%) 0.488 
Ramsay sedation score    
 PACU arrival 2 [1-2] 2 [2-2] 0.058 
 30 min at PACU  2 [1-2] 2 [2-2] >0.999 
 1 h after PACU discharge  2 [1-2] 2 [2-2] 0.503 
 6 h after PACU discharge 2 [1-2] 2 [2-2] >0.999 
 24 h after PACU 
discharge 
2 [1-2] 2 [2-2] >0.999 
Data are presented as median (interquartile range) and numbers (%). 
PACU, post-anesthesia care unit 
 
Discussion 
This prospective, double-blind, randomized 
controlled trial in patients undergoing laparoscopic 
nephrectomy showed no difference in the incidence of 
PONV between sufentanil-based and fentanyl-based 
IV-PCA. Additionally, the intensity of PONV and the 
postoperative pain profiles were comparable between 
the two treatment groups. 
 Despite many dedicated efforts to reduce the 
incidence of PONV, it still remains “the big little 
problem”, as Kapur described. [24] The mechanisms of 
PONV are multifactorial, and Apfel’s risk factors for 
PONV include female gender, non-smoker, 
postoperative opioid use, and a history of PONV or 
motion sickness.[4] Among these, postoperative 
opioid use is the only correctable factor; although, the 
use of opioids is inevitable after major surgery. 
Therefore, current strategies to manage and prevent 
PONV focus on the avoidance of higher doses of 
opioids and choosing an appropriate type of opioid as 
well as prophylactic administration of antiemetic 
drugs.[8,25,26]  
 Although there is still debate regarding whether 
the type of surgery contributes to the development of 
PONV, laparoscopic surgery has a potential to 
increase the incidence of PONV compared with open 
surgery due to the use of CO2 pneumoperitoneum, 
which results in peritoneal distension and visceral 
irritation.[27] In a previous study, Yamanaga et al. 
reported an incidence of PONV higher than 60% in 
patients undergoing laparoscopic donor 
nephrectomy.[28] Therefore, an opioid-based PCA 
regimen with a lower risk of PONV is particularly 
important among high-risk laparoscopic surgery 
patients. 
In this present study of patients undergoing 
laparoscopic nephrectomy, the incidence of PONV at 
24 h after PACU discharge was 64.3% in the sufentanil 
group and 65% in the fentanyl group without 
significant difference. A possible explanation for this 
high incidence of PONV is that more than 50% of 
patients had Apfel scores of 3 or 4 in both groups. In a 
previous study comparing sufentanil- and 
fentanyl-based IV-PCA after lumbar fusion, the 
incidences of PONV was 4.76% and 28.5% in the 
sufentanil and fentanyl groups, respectively, even 
though they used higher doses of sufentanil (4 µg/kg) 
and fentanyl (24 µg/kg) than those in this study.[14] 
Considering that Kim et al and Choi et al reported 
approximately 70% incidence of PONV in highly 
susceptible patients undergoing lumbar 
surgery,[29,30] while Park et al reported 
approximately 30% incidence with a similar dose of 
fentanyl-based IV-PCA in patients at moderate risk 
undergoing lumbar surgery,[31] the PONV risk itself, 
in other words, individual patients’ susceptibility may 
be important in the development of PONV. [32] 
Furthermore, a lower incidence of PONV in the 
sufentanil group than that in the fentanyl group in the 
Kim et al’s study [14] was possibly due to the lower 
proportion of females, consequently leading to a 
lower risk of PONV. 
Numerous previous studies comparing 
sufentanil and fentanyl have focused on intrathecal 
injection, epidural PCA, and intraoperative 
infusion.[8,33,34] Few studies have compared the 
effect of sufentanil- and fentanyl-based IV-PCA on the 
relative emetic potencies. Opioid-induced nausea and 
vomiting occur via stimulation of the CTZ or the 
vestibular apparatus, mediated by activation of the 
opioid mu receptor.[35,36] Notably, the CTZ is 
located outside the blood-brain barrier and contains a 
high concentration of opioid receptors. Therefore, the 
CTZ is susceptible to opioid stimulation.[36] 
Sufentanil has an 8-10 times higher lipid solubility 
than fentanyl, with a higher affinity for the mu-opioid 
receptor, and 5-10 times more potency than fentanyl; 
thus, smaller doses are required to achieve an 
analgesic effect. [11] Because the opioid-induced 
PONV risk increases in a dose-dependent manner,[2] 
it has been suggested that sufentanil-based IV-PCA 
provide a powerful analgesic effect with a lower 
incidence of PONV than fentanyl-based IV-PCA. 
Contrary to our expectation, the incidence of 
PONV was similar between the groups. The intensity 
of PONV reported by the modified Rhodes index at 24 
h after surgery, the number of patients who required 
rescue antiemetics was also comparable throughout 
the study period. Because pain increases the incidence 
of PONV, we compared pain profiles, and there were 
no differences in pain profiles between the groups. 
The incidences of other opioid-related side effects, 
including dizziness and pruritis, were similar, and no 
patients reported excessive sedation in each group. 
Based on the results that there were no differences in 




all comparative values between the two groups, we 
suggest that the sufentanil and fentanyl dose ratio 
used in this study (1: 7) seems to be clinically 
equivalent. 
It is noteworthy that the PCA satisfaction score 
and pain profiles were similar between patients with 
and without PONV; although, more patients with 
PONV stopped IV-PCA and required antiemetics. 
Therefore, this regimen of IV-PCA seems to be 
adequate for pain control in laparoscopic 
nephrectomy. Because ketorolac is also added to 
lower the opioid dose, other methods, such as adding 
two or more antiemetics with different mechanisms of 
action, should be considered to lower the incidence of 
PONV in moderate- to high-risk patients.[37] 
Alternatively, considerably lower opioid doses may 
be needed for pain relief based on the fact that mutant 
variant of mu-opioid receptor genes is more sensitive 
and prevalent in Asian populations.[38] However, 
this is beyond the scope of this study and will not 
discussed further here. 
  This study has limitations. The severity of 
PONV, which was evaluated by the modified Rhodes 
index, was assessed only at 24 h after PACU 
discharge. Although the incidence of PONV did not 
differ at each time point, there is a possibility that the 
severity of PONV might be different between the 
groups at different time point. However, we 
estimated the severity of PONV through the incidence 
of PONV and the number of patients who required 
antiemetics at each time point. 
 In conclusion, sufentanil-based and 
fentanyl-based IV-PCA showed a similar incidence of 
PONV with comparable analgesic effects after 
laparoscopic nephrectomy. Based on these results, we 
suggest that sufentanil and fentanyl may provide 
comparable effects for PCA after laparoscopic 
nephrectomy.  
Abbreviations 
ASA: american society of anesthesiologists; BIS: 
bispectral index; CO2: carbon dioxide; CTZ: 
chemoreceptor trigger zone; IV-PCA: intravenous 
patient-controlled analgesia; PACU: post-anesthesia 
care unit; PONV: postoperative nausea and vomiting; 
VNRS: verbal numerical rating scale. 
Acknowledgments 
We wish to thank Won-Hee Baek and Mirr Moon 
for participating in this study. 
Funding 
This work was supported in part by a research 
grant from the BC World Pharm. The opinions 
expressed in this paper are those of the authors and 
do not necessarily represent those of BC World 
Pharm. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 
2006; 102(6):1884-98. 
2. Roberts GW, Bekker TB, Carlsen HH, Moffatt CH, Slattery PJ, McClure AF. 
Postoperative nausea and vomiting are strongly influenced by postoperative 
opioid use in a dose-related manner. Anesthesia & Analgesia 2005; 
101(5):1343-8. 
3. Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative 
interview: assessing risk factors for nausea and vomiting. Anesth Analg 1994; 
78(1):7-16. 
4. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, et al. A factorial 
trial of six interventions for the prevention of postoperative nausea and 
vomiting. N Engl J Med 2004; 350(24):2441-51. 
5. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, 
treatment, and prevention. Anesthesiology 1992; 77(1):162-84. 
6. Karanicolas PJ, Smith SE, Kanbur B, Davies E, Guyatt GH. The impact of 
prophylactic dexamethasone on nausea and vomiting after laparoscopic 
cholecystectomy: a systematic review and meta-analysis. Ann Surg 2008; 
248(5):751-62. 
7. Patrick M, Eagar BM, Toft DF, Sebel PS. Alfentanil-supplemented anaesthesia 
for short procedures. A double-blind comparison with fentanyl. Br J Anaesth 
1984; 56(8):861-6. 
8. Langevin S, Lessard MR, Trepanier CA, Baribault JP. Alfentanil causes less 
postoperative nausea and vomiting than equipotent doses of fentanyl or 
sufentanil in outpatients. Anesthesiology 1999; 91(6):1666-73. 
9. Nie Y, Liu Y, Luo Q, Huang S. Effect of dexmedetomidine combined with 
sufentanil for post-caesarean section intravenous analgesia: a randomised, 
placebo-controlled study. Eur J Anaesthesiol 2014; 31(4):197-203. 
10. Maciejewski D. Sufentanil in anaesthesiology and intensive therapy. 
Anaesthesiol Intensive Ther 2012; 44(1):35-41. 
11. Leysen JE, Gommeren W, Niemegeers CJ. [3H]Sufentanil, a superior ligand for 
mu-opiate receptors: binding properties and regional distribution in rat brain 
and spinal cord. Eur J Pharmacol 1983; 87(2-3):209-25. 
12. Rosow CE. Sufentanil citrate: a new opioid analgesic for use in anesthesia. 
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 
1984; 4(1):11-8. 
13. Lin CS, Lu G, Ruan LY, Gu MN. [Patient-controlled intravenous analgesia 
with sufentanil and fentanyl after thoracotomy: a comparative study]. Nan 
Fang Yi Ke Da Xue Xue Bao 2006; 26(2):240-1, 4. 
14. Kim DK, Yoon SH, Kim JY, Oh CH, Jung JK, Kim J. Comparison of the Effects 
of Sufentanil and Fentanyl Intravenous Patient Controlled Analgesia after 
Lumbar Fusion. J Korean Neurosurg Soc 2017; 60(1):54-9. 
15. Rhodes VA, McDaniel RW. The Index of Nausea, Vomiting, and Retching: a 
new format of the lndex of Nausea and Vomiting. Oncol Nurs Forum 1999; 
26(5):889-94. 
16. Kim S-H, Oh C-S, Lee SJ. Efficacy of palonosetron and ramosetron on 
postoperative nausea and vomiting related to intravenous patient-controlled 
analgesia with opioids after gynecological laparoscopic surgery 
(double-blinded prospective randomized controlled trial). J Anesth 2015; 
29(4):585-92. 
17. Oh CS, Jung E, Lee SJ, Kim SH. Effect of nefopam- versus fentanyl-based 
patient-controlled analgesia on postoperative nausea and vomiting in patients 
undergoing gynecological laparoscopic surgery: a prospective double-blind 
randomized controlled trial. Curr Med Res Opin 2015; 31(8):1599-607. 
18. Wang X, Liu W, Xu Z, Wang F, Zhang C, Wang B, et al. Effect of 
Dexmedetomidine Alone for Intravenous Patient-Controlled Analgesia After 
Gynecological Laparoscopic Surgery: A Consort-Prospective, Randomized, 
Controlled Trial. Medicine (Baltimore) 2016; 95(19):e3639. 
19. Wang N, Zhou H, Song X, Wang J. Comparison of oxycodone and sufentanil 
for patient-controlled intravenous analgesia after laparoscopic radical 
gastrectomy: A randomized double-blind clinical trial. Anesth Essays Res 
2016; 10(3):557-60. 
20. Chen XH, Wang ZJ, Xiang QM, Zheng JW. [Effect of dexmedetomidine alone 
for postoperative analgesia after laparoscopic cholecystectomy]. Zhonghua Yi 
Xue Za Zhi 2017; 97(4):295-9. 
21. Park JH, Lee C, Shin Y, An JH, Ban JS, Lee JH. Comparison of oxycodone and 
fentanyl for postoperative patient-controlled analgesia after laparoscopic 
gynecological surgery. Korean J Anesthesiol 2015; 68(2):153-8. 
22. Zhang XK, Chen QH, Wang WX, Hu Q. Evaluation of dexmedetomidine in 
combination with sufentanil or butorphanol for postoperative analgesia in 
patients undergoing laparoscopic resection of gastrointestinal tumors: A 
quasi-experimental trial. Medicine (Baltimore) 2016; 95(50):e5604. 




23. Wang J, Ma H, Zhou H, Gao Y, Fu Y, Wang N. Effect of preoperative 
intravenous oxycodone administration on sufentanil consumption after 
retroperitoneal laparoscopic nephrectomy. Anaesthesiol Intensive Ther 2016; 
48(5):300-4. 
24. Kapur PA. The big "little problem". Anesth Analg 1991; 73(3):243-5. 
25. Ziemann-Gimmel P, Goldfarb AA, Koppman J, Marema RT. Opioid-free total 
intravenous anaesthesia reduces postoperative nausea and vomiting in 
bariatric surgery beyond triple prophylaxis. Br J Anaesth 2014; 112(5):906-11. 
26. Moon YE. Postoperative nausea and vomiting. Korean J Anesthesiol 2014; 
67(3):164-70. 
27. Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, et al. 
Evidence-based analysis of risk factors for postoperative nausea and vomiting. 
Br J Anaesth 2012; 109(5):742-53. 
28. Yamanaga S, Posselt AM, Freise CE, Kobayashi T, Tavakol M, Kang SM. A 
Single Perioperative Injection of Dexamethasone Decreases Nausea, Vomiting, 
and Pain after Laparoscopic Donor Nephrectomy. J Transplant 2017; 
2017:3518103. 
29. Kim EJ, Shim JK, Soh S, Song JW, Lee SR, Kwak YL. Patient-controlled 
Analgesia With Propacetamol-Fentanyl Mixture for Prevention of 
Postoperative Nausea and Vomiting in High-risk Patients Undergoing Spine 
Surgery: A Randomized Controlled Trial. J Neurosurg Anesthesiol 2016; 
28(4):316-22. 
30. Choi YS, Shim JK, Yoon DH, Jeon DH, Lee JY, Kwak YL. Effect of ramosetron 
on patient-controlled analgesia related nausea and vomiting after spine 
surgery in highly susceptible patients: comparison with ondansetron. Spine 
(Phila Pa 1976) 2008; 33(17):E602-6. 
31. Park JH, Shim JK, Song JW, Jang J, Kim JH, Kwak YL. A Randomized, 
Double-blind, Non-inferiority Trial of Magnesium Sulphate versus 
Dexamethasone for Prevention of Postoperative Sore Throat after Lumbar 
Spinal Surgery in the Prone Position. Int J Med Sci 2015; 12(10):797-804. 
32. Janicki PK, Vealey R, Liu J, Escajeda J, Postula M, Welker K. Genome-wide 
association study using pooled DNA to identify candidate markers mediating 
susceptibility to postoperative nausea and vomiting. Anesthesiology 2011; 
115(1):54-64. 
33. Jeon HR, Chae WS, Lee SJ, Lee JH, Cho SH, Kim SH, et al. A comparison of 
sufentanil and fentanyl for patient-controlled epidural analgesia in 
arthroplasty. Korean J Anesthesiol 2011; 60(1):41-6. 
34. Kim SY, Cho JE, Hong JY, Koo BN, Kim JM, Kil HK. Comparison of intrathecal 
fentanyl and sufentanil in low-dose dilute bupivacaine spinal anaesthesia for 
transurethral prostatectomy. Br J Anaesth 2009; 103(5):750-4. 
35. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid 
analgesics during treatment of chronic pain: mechanisms, implications, and 
management options. Pain Med 2009; 10(4):654-62. 
36. Silva AC, O'Ryan F, Poor DB. Postoperative nausea and vomiting (PONV) 
after orthognathic surgery: a retrospective study and literature review. J Oral 
Maxillofac Surg 2006; 64(9):1385-97. 
37. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. 
Consensus guidelines for the management of postoperative nausea and 
vomiting. Anesth Analg 2014; 118(1):85-113. 
38. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of 
the mu-opioid receptor influences intrathecal fentanyl analgesia requirements 
in laboring women. Pain 2008; 139(1):5-14. 
 
